These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22844126)

  • 1. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
    Sun Y; Rha S; Lee SH; Guo J; Ueda T; Qin S; Naito S; Cincotta M; Tokushige K; Akaza H
    Jpn J Clin Oncol; 2012 Sep; 42(9):836-44. PubMed ID: 22844126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
    Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study.
    Sugiyama S; Sato K; Shibasaki Y; Endo Y; Uryu T; Toyoshima Y; Oya M; Miyanaga N; Saijo N; Gemma A; Akaza H
    Jpn J Clin Oncol; 2020 Aug; 50(8):940-947. PubMed ID: 32458996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
    Nozawa M; Nonomura N; Ueda T; Nishimura K; Kanayama HO; Miki T; Nakatani T; Tomita Y; Azuma H; Yoshioka T; Tsujihata M; Uemura H
    Jpn J Clin Oncol; 2013 Nov; 43(11):1132-8. PubMed ID: 23999768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
    Plimack ER; Tan T; Wong YN; von Mehren MM; Malizzia L; Roethke SK; Litwin S; Li T; Hudes GR; Haas NB
    Oncologist; 2014 Apr; 19(4):354-5. PubMed ID: 24674872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma.
    Lee JB; Park HS; Park S; Lee HJ; Kwon KA; Choi YJ; Kim YJ; Nam CM; Cho NH; Kang B; Chung HC; Rha SY
    Cancer Res Treat; 2019 Oct; 51(4):1578-1588. PubMed ID: 30999721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
    World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temsirolimus: in advanced renal cell carcinoma.
    Simpson D; Curran MP
    Drugs; 2008; 68(5):631-8. PubMed ID: 18370442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
    Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF
    Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
    Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
    Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
    Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
    Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
    Merchan JR; Qin R; Pitot H; Picus J; Liu G; Fitch T; Maples WJ; Flynn PJ; Fruth BF; Erlichman C
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):485-93. PubMed ID: 25556030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
    Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
    Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
    Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
    Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
    Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.